Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 9/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459123 | 1.00 | SLC18A3 (0.60) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL18284733 | 1.00 | SLC18A3 (0.60) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL4483396 | 0.90 | SLC18A3 (0.69) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL22055105 | 0.88 | SLC18A3 (0.66) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL2965273 | 0.80 | SLC18A3 (0.81) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL30563652 | 0.77 | SLC18A3 (0.96) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL4334818 | 0.77 | GRIN2B (0.57) | SLC18A3GRIN2BCYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL27709432 | 0.76 | CYP2D6 (0.65) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL25993289 | 0.76 | SLC18A3 (0.64) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL7888827 | 0.75 | SLC18A3 (1.00) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | SLC18A3 3509/4885GRIN2B 3868/4885CYP2D6 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.